116 years of building, sharing and reinvesting in knowledge
A rich
legacy
Founded in 1908 and headquartered in Denmark, we are majority owned by the LEO Foundation
Medical dermatology
Dedicating decades of research and development to advance the science of dermatology
Our
purpose
Advancing the standard of care for the benefit of people with skin conditions, their families and society
NEWS ARTICLE
LEO Pharma delivers 7% revenue growth at CER in H1 2025 and achieves key milestones enabling future growth
In H1 2025, LEO Pharma delivered robust growth and significantly improved profitability, enabling an increase to the financial outlook for ...
Ballerup, Denmark, 18 August, 2025
2025 H1 Results- 18/08/25 LEO Pharma delivers 7% revenue growth at CER in H1 2025 and achieves key milestones enabling future growth
- 23/07/25 LEO Pharma Announces FDA Approval of ANZUPGO® (delgocitinib) Cream in the U.S.
- 14/07/25 Boehringer Ingelheim and LEO Pharma enter partnership to commercialize and further develop SPEVIGO® (spesolimab)
Our performance and results
LEO Pharma's Annual Report covers our financial and sustainability reporting for the financial year from January 1 to December 31.
Read our 2024 Annual Report
CAREER
Discover how we innovate collectively.
For us, collaborating innovatively means continuously enhancing and expanding what's achievable for one another, our company, and our patients.
Learn more
